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Main Findings for 2014 
 
• For 2014, CDC was notified of a total of 1,744 U.S. cases of babesiosis, a 1% decrease from the total of 
1,761 cases for 2013. 
• Babesiosis was a reportable disease in 31 states in 2014 (compared with 27 states in 2013); 22 
(71%) of the 31 states notified CDC of at least 1 case.  
• Most of the reported cases (94%; n = 1,636/1,744) were in residents of 7 states in the Northeast and 
upper Midwest (Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and 





Babesiosis is caused by protozoan parasites of the genus Babesia, which infect red blood cells. Babesia 
parasites usually are tickborne but also can be transmitted via blood transfusion or congenitally (1–3). 
 
Most human cases of Babesia infection in the United States are caused by the parasite Babesia microti. 
Occasional U.S. cases caused by other species (types) of Babesia have been detected (4, 5). Babesia microti is 
spread in nature by Ixodes scapularis ticks (also called blacklegged ticks or deer ticks)—primarily in the 
Northeast and upper Midwest, especially in parts of New England, New York State, New Jersey, Wisconsin, 
and Minnesota (1, 6–8). The parasite B. microti typically is spread by the young nymph stage of the tick, 
which is found mostly during warm months (spring and summer), in areas with woods, brush, or grass. 
Infected people might not recall a tick bite because I. scapularis nymphs are very small (about the size of a 
poppy seed). 
 
Many people who are infected with Babesia microti are asymptomatic. Some people develop flu-like 
symptoms, such as fever, chills, sweats, headache, body aches, loss of appetite, nausea, or fatigue. Because 
Babesia parasites infect and destroy red blood cells, babesiosis causes hemolytic anemia, which may range 
from mild to marked (7). 
 
Babesiosis can be a severe, life-threatening disease (1, 7), particularly in people who: 
• do not have a spleen; 
• have a weak immune system for other reasons (such as cancer, lymphoma, or AIDS); 
• have other serious health conditions (such as liver or kidney disease); or 




CDC has conducted surveillance for babesiosis in the United States since January 2011, when babesiosis 
became a nationally notifiable condition. The babesiosis case definition used for surveillance purposes is 
available online (http://wwwn.cdc.gov/nndss/conditions/babesiosis/case-definition/2011/) and is 
summarized in Table 1. Health departments in states where babesiosis is reportable notify CDC of cases that 
meet the definition via the National Notifiable Disease Surveillance System (NNDSS). 
 
Health departments submit additional information about reported cases using the CDC Case Report Form 
(CRF) Babesiosis CRF  [PDF, 2 pages, 650 KB]; data are requested about risk factors for infection, 
clinical manifestations, and laboratory results. For more information, visit babesiosis surveillance and 
case reporting. Health care providers, laboratories, and the general public should contact their state health 
department for information about reporting cases of babesiosis.  
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The number of states in which babesiosis is a reportable condition may change from year to year as 
additional states begin conducting surveillance. Cases are reported by state and county of residence, which is 
not necessarily where the exposure occurred. Changes in the number of reported cases do not necessarily 
represent true changes in disease incidence; ascertainment, reporting, and investigation of cases are subject 
to clinician awareness and public health agency resources, which may vary from year to year in and among 
states. 
 
This summary focuses on babesiosis cases reported for surveillance year 2014; some data from previous 
years (2011–2013) are included to show differences from year to year. Babesiosis surveillance data also are 
summarized in CDC's Morbidity and Mortality Weekly Report (MMWR) weekly and annual summaries of 
nationally notifiable diseases. In addition, national surveillance data for 2011 were published previously (8). 
Because of differences in the timeline for finalizing data in the annual surveillance datasets, data provided in 
this summary may differ slightly from those previously published. Of note, the year in which a case is 
counted in national surveillance summaries is assigned by the health department and might reflect the year 
of symptom onset, diagnosis, or of reporting to or by the health department. 
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Table 1. National surveillance case definition for babesiosis* 
 
Clinical evidence Objective 
One or more of the following: fever, anemia, or thrombocytopenia. 
 
Subjective 





For the purposes of surveillance, epidemiologic linkage between a transfusion 
recipient and a blood donor is demonstrated if all of the following criteria are met: 
 
In the transfusion recipient 
Received one or more red blood cell (RBC) or platelet transfusions within 1 year 
before the collection date of a specimen with laboratory evidence of Babesia 
infection; and 
 
At least one of these transfused blood components was donated by the donor 
described below; and 
 
Transfusion-associated infection is considered at least as plausible as tickborne 
transmission; and 
 
In the blood donor 
Donated at least one of the RBC or platelet components that was transfused into 
the above recipient; and 
 
The plausibility that this blood component was the source of infection in the 
recipient is considered equal to or greater than that of blood from other involved 





Identification of intraerythrocytic Babesia organisms by light microscopy in a 
Giemsa, Wright, or Wright-Giemsa–stained blood smear; or 
 
Detection of Babesia microti DNA in a whole blood specimen by polymerase chain 
reaction (PCR); or 
 
Detection of Babesia spp. genomic sequences in a whole blood specimen by 
nucleic acid amplification; or 
 




Demonstration of a Babesia microti indirect fluorescent antibody (IFA) total 
immunoglobulin (Ig) or IgG antibody titer of ≥1:256 (or ≥1:64 in 
epidemiologically linked blood donors or recipients); or 
 
Demonstration of a Babesia microti immunoblot IgG positive result; or 
 
Demonstration of a Babesia divergens IFA total Ig or IgG antibody titer of ≥1:256; 
or 
Demonstration of a Babesia duncani IFA total Ig or IgG antibody titer of ≥1:512. 
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Case classification 
Confirmed A case that has confirmatory laboratory results and meets at least one of the objective 
or subjective clinical evidence criteria, regardless of the mode of transmission (can 
include clinically manifest cases in transfusion recipients or blood donors). 
Probable A case that has supportive laboratory results and meets at least one of the objective 
clinical evidence criteria (subjective criteria alone are not sufficient); or 
 
A case that is in a blood donor or recipient epidemiologically linked to a confirmed or 
probable babesiosis case (as defined above) and 
 
Has confirmatory laboratory evidence but does not meet any objective or 
subjective clinical evidence criteria; or 
 
Has supportive laboratory evidence and might or might not meet any 
subjective clinical evidence criteria but does not meet any objective clinical 
evidence criteria. 
 
* Available at http://wwwn.cdc.gov/nndss/conditions/babesiosis/case-definition/2011/  
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2014 babesiosis surveillance summary 
 
In 2014, babesiosis was a reportable condition in 31 states (compared with 27 states in 2013). CDC was 
notified of a total of 1,744 cases of babesiosis by 22 (71%) of the 31 states (Table 2), a 1% decrease from the 
total of 1,761 cases for 2013 (Figure 1). Among the 22 states that reported at least 1 case of babesiosis for 
2014, 94% (n = 1,636/1,744) of the reported cases were in residents of 7 states (Connecticut, Massachusetts, 
Minnesota, New Jersey, New York, Rhode Island, and Wisconsin). Tickborne transmission of Babesia 
parasites is well established in parts of these states. Differences within and among states in the distributions 
of reported cases by place of residence are evident in the county-level maps for 2014 (Figure 2) and the 3 
prior years (2011, 2012, and 2013) in which national surveillance was conducted (Appendix). Changes in 
the number of states conducting surveillance for babesiosis had minimal impact on the fluctuations in the 
yearly totals of cases. For example, among the 4 states that added babesiosis to their lists of reportable 
conditions in 2014, Illinois and Ohio each reported only 1 case, and neither Montana nor Utah reported any 
cases for 2014. 
 
For 2014, the median age of the case-patients was 63 years (range: <1–96 years; n = 1,741). The age 
distributions for 2014 and the 3 previous years were similar (Figure 3), with the largest number of cases 
reported in persons aged 60–69 years. Similar to the data for previous years, for 2014, among the 1,744 
case-patients, 65% (n = 1,131) were male, 35% were female, and the sex was unknown for <1%. 
 
A majority of case-patients have reported getting sick during the spring or summer months (Figure 4). Data 
on month of symptom onset were available for most case-patients (overall, n = 4,268/5,542; 2011, n = 
932/1,126; 2012, n = 644/911; 2013, n = 1,352/1,761; 2014, n = 1,340/1,744). The proportion of case-
patients with reported symptom onset during June–August has remained fairly consistent from year to year: 
81% for 2011 (n = 759/932); 72% for 2012 (n = 464/644); 86% for 2013 (n = 1,156/1,352); and 84% for 
2014 (n = 1,124/1,340). 
 
For 2014, among the case-patients for whom data were available, fever was the most frequently reported 
clinical manifestation (83%; n = 1,258/1,511 patients), followed by chills (69%; n = 815/1,178), 
thrombocytopenia (69%; n = 546/796), myalgia (68%; n = 819/1,213), and anemia (62%; n = 514/829). 
 
For 2014, hospitalization data were available for 1,500 case-patients, 681 (45%) of whom reportedly had 
been hospitalized for at least 1 day; the median length of the hospital stay was 3 days (range: 1–35 days) 
among the 210 case-patients with available data. Overall for 2011–2014, hospitalization data were available 
for 4,569 case-patients (82% of the total of 5,542), 2,165 of whom (47% of 4,569) reportedly had been 
hospitalized for at least 1 day (Figure 5); the median length of the hospital stay was 4 days (range: 1–39 
days) among the 870 case-patients with available data. 
 
For 2014, of the 756 case-patients for whom data were available, 359 (47%) recalled having a tick bite in the 
8 weeks before symptom onset. Overall for 2014, 6 cases of babesiosis in blood recipients were classified by 
the reporting state as transfusion associated.  
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Table 2. Number and incidence of reported cases of babesiosis, by state and year, 2011–2014* 
 
 2011 2012 2013 2014 
State† No. Rate‡ No. Rate No. Rate No. Rate 
Alabama 1 <0.1 0 0.0 0 0.0 1 <0.1 
Alaska —§ — — — — — — — 
Arizona — — — — — — — — 
Arkansas — — — — — — — — 
California 1 <0.1 4 <0.1 3 <0.1 3 <0.1 
Colorado — — — — — — — — 
Connecticut 74 2.1 123 3.4 268 7.5 205 5.7 
Delaware 1 0.1 0 0.0 2 0.2 1 0.1 
District of Columbia — — — — — — — — 
Florida — — — — — — — — 
Georgia — — — — — — — — 
Hawaii — — — — — — — — 
Idaho — — — — — — — — 
Illinois — — — — — — 1 <0.1 
Indiana 0 0.0 1 <0.1 1 <0.1 0 0.0 
Iowa — — — — — — — — 
Kansas — — — — — — — — 
Kentucky — — — — — — — — 
Louisiana — — — — 2 <0.1 0 0.0 
Maine 9 0.7 10 0.8 36 2.7 42 3.2 
Maryland 4 0.1 3 0.1 9 0.2 2 <0.1 
Massachusetts 208 3.1 261 3.9 417 6.2 537 8.0 
Michigan 0 0.0 0 0.0 2 <0.1 2 <0.1 
Minnesota 73 1.4 41 0.8 64 1.2 49 0.9 
Mississippi — — — — — — — — 
Missouri — — — — — — — — 
Montana — — — — — — 0 0.0 
Nebraska 0 0.0 1 0.1 1 0.1 0 0.0 
Nevada — — — — — — — — 
New Hampshire 13 1.0 19 1.4 22 1.7 42 3.2 
New Jersey 166 1.9 92 1.0 171 1.9 159 1.8 
New Mexico — — — — — — — — 
New York 418 2.1 253 1.3 534 2.7 471 2.4 
North Carolina — — — — — — — — 
North Dakota 1 0.1 0 0.0 1 0.1 0 0.0 
Ohio — — — — — — 1 <0.1 
Oklahoma — — — — — — — — 
Oregon 1 <0.1 0 0.0 0 0.0 1 <0.1 
Pennsylvania — — — — — — — — 
Rhode Island 73 6.9 56 5.3 142 13.5 172 16.3 
South Carolina — — — — 1 <0.1 3 0.1 
South Dakota — — — — 1 0.1 1 0.1 
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Tennessee 1 <0.1 0 0.0 0 0.0 0 0.0 
Texas — — — — 1 <0.1 1 <0.1 
Utah — — — — — — 0 0.0 
Vermont 2 0.3 2 0.3 6 1.0 3 0.5 
Virginia — — — — — — — — 
Washington 0 0.0 0 0.0 1 <0.1 4 0.1 
West Virginia — — — — 0 0.0 0 0.0 
Wisconsin 80 1.4 45 0.8 76 1.3 43 0.7 
Wyoming 0 0.0 0 0.0 0 0.0 0 0.0 
Total¶ 1,126 0.8 911 0.6 1,761 1.0 1,744 0.8 
 
* Year as reported by the health department 
† Cases were reported by state of residence, which was not necessarily the state of exposure. 
‡ Rate per 100,000 population (9) 
§ Not reportable 
¶ The denominators for calculations of total incidence rates included only the populations of states in which babesiosis 
was a reportable condition during the pertinent year. 
 
 
Figure 1. Number of reported cases of babesiosis, by year, 2011–2014* 
 
 






















Surveillance for Babesiosis — United States, 2014 
 
11 
February 29, 2016 
  




* N = 1,731; county of residence was known for all but 13 (1%) of the 1,744 total case-patients. See the Appendix for the 
maps for surveillance years 2011, 2012, and 2013. 
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Figure 3. Number of reported cases of babesiosis, by age group and year, 2011–2014* 
 
 
* Data on age were available for most case-patients (2011, n = 1,034/1,126; 2012, n = 785/911; 2013, n = 1,523/1,761; 
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Figure 4. Number of reported cases of babesiosis, by month and year of symptom onset, 2011–2014* 
 
 
* Data on month of symptom onset were available for most case-patients (2011, n = 932/1,126; 2012, n = 644/911; 
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Figure 5. Hospitalization data for babesiosis case-patients, all years combined, 2011–2014* 
 
 
* Hospitalization data were available for 4,569 case-patients (82% of the total of 5,542 for 2011–2014), 2,165 of whom 
(47% of 4,569) reportedly had been hospitalized for at least 1 day. The median length of the hospital stay was 4 days 
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Appendix. Maps for surveillance years 2011, 2012, and 2013 
 
 




* N = 1,117; county of residence was known for all but 9 (1%) of the 1,126 total case-patients. 
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* N = 904; county of residence was known for all but 7 (1%) of the 911 total case-patients. 
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* N = 1,749; county of residence was known for all but 12 (1%) of the 1,761 total case-patients. 
